Ondansetron, granisetron and dolasetron are antiemetics with 5-HT3 receptor antagonist activity, both in the central nervous system and gastrointestinal tract and have an antiemetic effect equivalent to maropitant.
Dolasetron has also been associated with prolongation of the QT interval in humans, with hypokalemia as a risk factor. This has also been reported with use of cisapride in humans.
The empirical dosage for use of dolasetron is 0.6 - 1.0 mg/kg IV or PO once daily; ondasetron dosage is 0.5 mg/kg IV or PO twice daily.
- Sedlacek HS et al (2008) Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. J Vet Pharmacol Ther 31(6):533-537
- Goodin, S & Cunningham, R (2002) 5-HT(3)-receptro antagonists for the treatment of nausea and vomiting; a reappraisal of their side-effect profile. Oncologist 7:424-436